Last reviewed · How we verify
GP40321
GP40321 is a small molecule that targets the serotonin receptor.
GP40321 is a small molecule that targets the serotonin receptor. Used for Treatment-resistant depression.
At a glance
| Generic name | GP40321 |
|---|---|
| Also known as | insulin glulisine |
| Sponsor | Geropharm |
| Drug class | Serotonin receptor antagonist |
| Target | 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
GP40321 acts as a selective serotonin receptor antagonist, which helps to modulate the activity of serotonin in the body. This mechanism is thought to contribute to its therapeutic effects.
Approved indications
- Treatment-resistant depression
Common side effects
- Nausea
- Headache
- Dizziness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GP40321 CI brief — competitive landscape report
- GP40321 updates RSS · CI watch RSS
- Geropharm portfolio CI